Results 31 to 40 of about 411,749 (186)

Subgroups of Adult‐Onset Diabetes: A Prospective Follow‐Up Study of Progression of Insulin Resistance and Deficiency and Association With Liver Steatosis and Fibrosis

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8004-8015, September 2026.
ABSTRACT Aims To assess progression of insulin deficiency and resistance in diabetes, the stability of cluster‐based subgrouping, and the association between steatotic liver disease (SLD), liver fibrosis (LF), and tissue insulin resistance. Materials and Methods Participants from a regional diabetes register were studied within 3 years from diagnosis ...
Aleksi Laitinen, Annemari Käräjämäki, Aki J. Käräjämäki, Samu Kurki, Liisa Hakaste, Olof Asplund, Johan Hultman, Kaj Lahti, Mikko Lehtovirta, Emma Ahlqvist, Tiinamaija Tuomi   +10 more
wiley   +1 more source

How the First 9 Months Shape the Rest of Your Life: The Impact of Gestational Diabetes on the Metabolic Future

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7705-7718, September 2026.
ABSTRACT Gestational diabetes mellitus (GDM) represents far more than a transient glycaemic disorder: it is a sentinel metabolic event that unveils pre‐existing defects in β‐cell function and insulin action, with profound implications for both maternal and offspring cardiometabolic health across the lifespan.
Mustafa Kanat, Muhammad Abdul‐Ghani, Ralph A. DeFronzo   +2 more
wiley   +1 more source

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia

ClinicoEconomics and Outcomes Research, 2020
Asrul Akmal Shafie,1 Chin Hui Ng2 1Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Penang, Malaysia; 2Pharmacy Department, Hospital Raja Permaisuri Bainun, Ipoh 30450, Perak, MalaysiaCorrespondence: Asrul Akmal ...
Shafie AA, Ng CH
doaj  

Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake? [PDF]

Diabetes Obes Metab, 2015
Insulin therapy is often associated with adverse weight gain. This is attributable, at least in part, to changes in energy balance and insulin's anabolic effects.
Russell-Jones D, Danne T, Hermansen K, Niswender K, Robertson K, Thalange N, Vasselli JR, Yildiz B, Häring HU.   +8 more
europepmc   +2 more sources

Impact of Early Subcutaneous Basal Insulin With Intravenous Insulin Infusion for Diabetic Ketoacidosis and Glycaemic Outcomes: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
Early subcutaneous basal insulin initiation alongside intravenous insulin significantly shortened diabetic ketoacidosis resolution time and modestly reduced fluid requirements without increasing adverse events, supporting its potential role as a safe adjunctive strategy in adult DKA management.
Abdallah AbuJlambo, Maha AbuZarifa, Rejean R. R. Sawh, Subhash Reddy Narayana Reddy N, Muhammad Bin Salman, Insiya Mohammed Rampurawala, Yara Ashour, Hazem Ayesh   +7 more
wiley   +1 more source

Detemir dan Glargine: Profil Keamanan, Efikasi dan Farmakoekonomi Insulin Long-acting [PDF]

, 2021
Diabetes melitus merupakan sebuah penyakit gangguan metabolik yang ditandai dengan adanya peningkatan kadar gula darah karena tubuh tidak dapat memproduksi insulin dengan efektif, sehingga diperlukan insulin buatan untuk mengontrol kadar gula darah ...
Sari, Nuraini Maulidina, Mutmainah, Noviary Nur, Hidayat, Luthfi   +2 more
core   +1 more source

Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6291-6300, July 2026.
ABSTRACT Aim To investigate adherence to and persistence with free combination therapy (daily basal insulin plus an injectable glucagon‐like peptide‐1 receptor agonist [GLP‐1 RA]) versus fixed‐ratio combination (FRC) therapy (basal insulin plus a GLP‐1 RA) among individuals with type 2 diabetes (T2D) in Japan.
Takeshi Miyatsuka, James Brash, Eleanor Davies, Elisabeth de Laguiche, Dorte Vistisen, Can Yin, Atif Adam   +6 more
wiley   +1 more source

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review

Diabetes, Metabolic Syndrome and Obesity, 2009
Gregory E PetersonDepartment of Internal Medicine, Des Moines University, USAObjective: To review insulin detemir for clinical use to better manage patients with type 1 and type 2 diabetes.Methods: A MEDLINE search, in English, from June 30 ...
Gregory E Peterson
doaj  

Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients

International Journal of Endocrinology, 2013
Aims. To examine the potential differences between multiple daily injection (MDI) regimens based on new long-acting insulin analogues (glargine or detemir) plus prandial insulin aspart and continuous subcutaneous insulin aspart infusion (CSII) in ...
Wen-shan Lv, Li Li, Jun-ping Wen, Rong-fang Pan, Rui-xia Sun, Jing Wang, Yu-xin Xian, Cai-xia Cao, Yan-yan Gao   +8 more
doaj   +1 more source

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, Volume 36, Issue 44, 1 June 2026.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source